Chief Medical Officer, Mark Berger, MD Discusses Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Genprex’s Chief Medical Officer, Mark Berger, MD, discusses positive clinical study updates from its Acclaim-1 and Acclaim-3 Phase 1/2 clinical trials in lung cancer and recent updates to the Company’s oncology clinical development program.